ReviewBone marrow transplantation2007
High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.
Review in Bone marrow transplantation, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Second auto-SCT for treatment of relapsed multiple myeloma.Bone marrow transplantation · 2013Trial
- Impact of Pre-transplant and Post-transplant Remission Status of Patients on Survival in Newly Diagnosed Multiple Myeloma.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2019Article
- Current therapeutic strategies for multiple myeloma.International journal of clinical oncology · 2015Review
- Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Article
- Article
- Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT.Bone marrow transplantation · 2013Article
- Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.Haematologica · 2013Article
- [Hematopoietic stem cell transplantation. Indications, foundations and perspective].Der Internist · 2009Review
- Optimal mobilization method and CD34+ dose calculation for autologous PBSC transplant in myeloma patients: two important unresolved questions.Bone marrow transplantation · 2009Article
- Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.Bone marrow transplantation · 2009Article
- Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?Bone marrow transplantation · 2009Article
- Treatment of myeloma: cure vs control.Mayo Clinic proceedings · 2008Review
- Impact of early relapse after auto-SCT for multiple myeloma.Bone marrow transplantation · 2008Article
- Current status of autologous hematopoietic stem cell transplantation in myeloma.Bone marrow transplantation · 2008Review
- Top Information Need Priorities of Older Adults Newly Diagnosed With Active Myeloma.Journal of the advanced practitioner in oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One or two cycles of high-dose chemotherapy with autologous hematopoietic stem cell transplantation have been shown to improve response rates and survival in myeloma. While this observation has largely been made in patients under the age of 65 years, there is evidence to suggest that the conclusions can be extrapolated to older individuals as well. In contrast to other hematologic malignancies treated with high-dose therapy, autografted myeloma patients continue to relapse several years after transplantation, and few patients are cured with this modality. However, up to a third of patients may be alive beyond a decade; some with excellent quality of life giving rise to the concept of 'operational cure'. Relapsing disease can be treated with novel agents or repeat high-dose chemotherapy and transplantation. The pressing questions to which answers are not obvious at the moment are whether tandem transplantation should be offered to all patients, and whether novel agents should be used before transplantation or reserved for relapse. Despite their excellent activity, there is no evidence so far that novel agents such as thalidomide, bortezomib and lenalidomide can replace high-dose chemotherapy and stem cell transplantation.
Indexed as
Identifiers
17680020What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.